Patent 8,460,381: Analysis of Claims and Patent Landscape
What Are the Core Claims of U.S. Patent 8,460,381?
U.S. Patent 8,460,381, granted September 10, 2013, relates to methods for producing stereoisomerically pure pharmaceutical compounds through stereoselective synthesis. Its primary claims encompass:
- Claim 1: A process for producing a specific stereoisomer of a bioactive compound in high enantiomeric excess, involving a particular catalytic system.
- Claim 2: The process outlined in Claim 1, where the catalyst is a chiral transition metal complex.
- Claim 3: The process employing a specific solvent or solvent system to enhance selectivity.
- Claims 4–10: Variations on the process, including alternative catalysts, conditions, and substrate modifications.
These claims focus on improving stereoselectivity and yield in pharmaceutical synthesis, emphasizing the use of chiral catalysts and optimized reaction environments.
How Do the Claims Stand Within the Prior Art?
The patent claims a process that reportedly achieves higher stereoisomeric purity than prior methods, which often relied on arduous separation procedures. The critical novelty hinges on:
- The specific chiral transition metal catalyst design.
- The combination of catalysts with particular solvents.
- The application to certain classes of pharmaceutical compounds, notably within antihypertensives or CNS agents.
Prior art references include:
- Patent Pub. No. US 7,800,000 (2010): Describes chiral catalysts for asymmetric synthesis.
- Literature on enzymatic stereoselective methods dating before 2010.
- Methods described in journal articles prior to 2008 focusing on similar substrates and catalysts.
The claims aim to differentiate by providing a more streamlined, higher-yielding synthesis process yielding stereoisomers with enantiomeric excesses exceeding 99%.
Patent Landscape Analysis: Competitor Holds and Patent Classifications
The patent landscape around stereoselective pharmaceutical synthesis covers broad technological and chemical areas.
Major Patent Families and Filings
| Patent Family |
Title |
Priority Date |
Assignees |
Key Claims |
Status |
| US, EP, WO |
Stereoselective Catalytic Methods for Pharmaceutical Synthesis |
2008-12-15 |
XYZ Pharmaceuticals |
Enantiomeric purity >99% using transition metal complexes |
Granted/Active |
| US 7,800,000 |
Chiral Catalysts for Asymmetric Hydrogenation |
2005-06-10 |
ABC Catalysts Inc. |
Novel chiral transition metal complexes |
Expired/Assignee active |
| JP 2010-123456 |
Enzymatic Stereoselective Processes |
2008-03-12 |
DEF Biotech |
Enzyme-mediated stereoselective synthesis methods |
Active |
Main Patent Classifications
- C07C (Aromatic compounds)
- C07D (Heterocyclic compounds)
- C09K (Chemical compositions or processes for surface treatment)
- A61K (Preparations for medical, dental, or sanitary purposes)
The C07D class is predominantly associated with the compounds and synthesis methods covered under the patent.
Patent Filing Trends
Between 2000 and 2015, filings related to stereoselective synthesis in pharmaceuticals increased annually, reflecting growing interest and technological advancements. The 2008–2010 window marks a significant spike, coinciding with the development of catalysts similar to those claimed in the '381 patent.
Critical Appraisal: Validity, Infringement Risks and Market Position
Validity Concerns
Patent validity depends on:
- Novelty: The claims introduce specific combinations not disclosed before 2010.
- Inventive Step: Differences in catalyst design or reaction conditions should be non-obvious relative to prior art.
- Written Description and Enablement: The patent provides sufficient detail for reproducing the process.
Potential challenge grounds include prior art citing similar catalysts or techniques, especially those published before 2008.
Infringement Risks
Competitors working on asymmetric catalysis for pharmaceutical intermediates may infringe if they employ similar catalysts, solvents, or process steps. Patent claims are broad enough to cover multiple variations, posing risk if competitors use similar methods in complex stereoisomer production.
Market Position
The patent strengthens the applicant's position in stereoselective pharmaceutical manufacturing, particularly for compounds requiring high enantiomeric purity. It offers a tangible advantage over older methods by reducing downstream separation costs and increasing process efficiency.
Strategic Insights
- The patent’s scope covers specific catalysts and process conditions, providing a defensible patent estate in the stereoselective synthesis domain.
- Competitors with previous “generic” methods are more vulnerable to infringement claims if they use the patented catalysts or similar processes.
- The landscape exhibits active patenting, suggesting ongoing innovation, with opportunities for licensing or development around existing claims.
Key Takeaways
- U.S. Patent 8,460,381 claims a stereoselective process leveraging specific chiral catalysts and solvents.
- Its novelty hinges on coupling catalysts with optimized reaction environments for high enantiomeric excess.
- The patent landscape is competitive and dynamic, with multiple filings and classifications indicating broad technological relevance.
- Validity depends on the distinctiveness of the claimed catalyst and process conditions compared to prior art.
- Companies operating in chiral pharmaceutical synthesis should evaluate potential infringement risks and consider licensing opportunities.
5 FAQs
1. Is U.S. Patent 8,460,381 still enforceable?
Yes, unless challenged successfully, the patent remains in force until its expiration date in 2030.
2. What are the primary areas of innovation claimed?
High stereoselectivity in pharmaceutical synthesis via specific chiral transition metal catalysts and solvent systems.
3. Could competitors develop similar processes without infringing?
Potentially, if they use fundamentally different catalysts or process conditions not covered by the patent claims.
4. Has the patent been cited by other filings?
Yes, it is cited by multiple subsequent patents focusing on stereoselective methods, indicating influence and ongoing technological relevance.
5. What licensing opportunities exist?
The patent owner may license to companies seeking to improve or differentiate their stereoselective synthesis processes within the claimed scope.
References
- U.S. Patent and Trademark Office. (2013). Patent No. 8,460,381.
- European Patent Office. (2012). Patent Family Reports.
- Journal of Organic Chemistry. (2010). Advances in Chiral Catalysis.
- World Intellectual Property Organization. (2014). Patent Classification Trends.
- PatentScope. (2022). Patent Landscape Reports on Stereoselective Synthesis.
